International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
Giorgio V. Scagliotti, Ihor O. Vynnychenko, Keunchil Park et al. · Journal of Clinical Oncology · 2012
PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml · min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. OS was the primary end point. Secondary end points included progression-free survival (PFS), objective response rate (ORR), adverse events (AEs), and association between placental growth factor (PLGF) change and OS. RESULTS: A total of 1,090 patients with nonsquamous NSCLC were randomly assigned (arms A/B, n = 541 of 549); of those, 890 had adenocarcinoma (n = 448 of 442). Median OS in arms A and B was 13.0 and 11.0 months, respectively (hazard ratio [HR], 0.90; 95% CI, 0.78 to 1.04; P = .14); median OS for the adenocarcinoma subset was 13.5 and 11.0 months, respectively (HR, 0.88; 95% CI, 0.75 to 1.03; P = .11). In descriptive analyses (arms A v B), median PFS was 5.6 months versus 5.4 months (P = < .001); ORR was 40% versus 26% (P < .001). There was no association between PLGF change and OS in arm A. The incidence of grade ≥ 3 AEs (arms A and B, 73% and 59%, respectively) and grade 5 AEs (14% and 9%, respectively) was higher with motesanib treatment. CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset.
Cited by 184 works. doi:10.1200/jco.2011.41.4987
Authors
- Giorgio V. Scagliotti
- Ihor O. Vynnychenko
- Keunchil Park
- Yukito Ichinose
- Kaoru Kubota
- Fiona Helen Blackhall
- Robert Pirker
- Rinat Galiulin
- Tudor–Eliade Ciuleanu
- Oleksandr Sydorenko
- Mircea Dediu
- Zsolt Pápai-Székely
- Natividad Martínez-Banaclocha
- Sheryl McCoy
- Yong-Jiang Hei
- Francesco Galimi
- David Robert Spigel
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Analysis of Survival Data
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- Biomarkers of response and resistance to antiangiogenic therapy